Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer relapse after radiotherapy is strongly predicted by biological markers.

2.

Glofitamab Regimen Improves Survival in DLBCL

3.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire

4.

Canadian Group Calls for Earlier Colorectal Cancer Screening

5.

Advancing Health in Africa


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot